Sign in

Research summary ·

Optic neuropathies induced by immune checkpoint inhibitors: A case series and systematic review of the literature.

Written based on 1 research study on PubMed, searched on 15 Nov 2026.

What was studied

Some cancer drugs are called immune checkpoint inhibitors. Rarely, they can cause harm to the optic nerve of the eye. The team looked back at such cases seen at their own centers. They also searched medical databases for cases others had reported. They sorted each case as optic neuritis or papillitis. In papillitis, the nerve head swells, but nerve scans and tests look normal.

What they found

The most common sign was blurred sight in both eyes, without pain. The nerve head was often swollen too. Everyone with optic neuritis had some loss of sight. Not everyone with papillitis had sight loss. People with papillitis also reported spots, flashes or floaters. Papillitis often came with uveitis, a problem inside the eye. Optic neuritis more often came with other nerve harm from the drugs. Even with drugs to calm the immune system, sight problems often stayed. This was even more common after optic neuritis. Some people with papillitis restarted the cancer drugs. The problem did not come back in them. One person with optic nerve harm also restarted without a relapse.

What it means for patients

The authors see separate forms of this nerve harm. Papillitis was tied to uveitis and Vogt-Koyanagi-Harada syndrome. Optic neuritis was tied to wider nerve harm and worse results. The authors suggest the drugs may be safely restarted after papillitis fully heals.

Why it is not certain yet

This side effect is rare, so there were not many cases to study. Part of the work looked back at past records. A review can only be as good as the studies in it. Only some people restarted the drugs. So the finding about restarting rests on few cases.

Source

Optic neuropathies induced by immune checkpoint inhibitors: A case series and systematic review of the literature.

PubMed · PMID 41759413

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Optic neuritis publications